Debate Over Antidepressants: FDA role in suppressing damaging data – WSJ

WSJ: Debate Over Antidepressants: FDA role in suppressing damaging data Tue, 25 May 2004 How were drug manufacturers able to conceal vital evidence of harmful antidepressant drug effects? The answer is becoming clearer by the day: federal regulators and the psychiatrists who tested these drugs in clinical trials are invested…

HMO physician applauds Spitzer’s focus on information bias / NYT blind spot

HMO physician applauds Spitzer’s focus on information bias / NYT blind spot Sun, 20 Jun 2004 The affirmation by a Kaiser Permanente physician, Dr. Kate Scannell, that NYS Attorney General, Eliot Spitzer, deserves applause for his “bold and courageous” lawsuit, is an encouraging watershed. The suit, she says, “gives me…

Public Servant or Private Marketer? NIH Seeks Inquiry of Alzheimer’s researcher conflicts of interest

NIH: Public Servant or Private Marketer? NIH Seeks Outside Inquiry of Alzheimer’s researcher conflicts of interest – LAT Mon, 31 Jan 2005 A year after the Los Angeles Times published its first an in-depth investigative report documenting in detail evidence of major conflicts of interest by top scientists at the…

Infomail Archive 2005

Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…

Data from Unpublished Trials Suggest that Most SSRIs Unsuitable for Children

Data from Unpublished Trials Suggest that Most SSRI Antidepressant Drugs Unsuitable for Children Wed, 21 Apr 2004 An independent analysis in next week’s The Lancet compares the published and unpublished data of pediatric SSRI antidepressant clinical trial data, finding the published reports not to be evidence-based. “In a global medical…

Pharma Efforts to Bar Placebo Responders from Trials – WSJ

Pharma Efforts to Bar Placebo Responders from Trials – WSJ Fri, 25 Jun 2004 A clinical trial report in The Lancet debunks the value of Aricept, a popular drug prescribed for Alzheimer’s patients. The findings of a three-year placebo controlled trial show that: “Although the patients taking the drug did…